Helen Mossop

DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer

Joaquı́n Mateo, Suzanne Carreira, Shahneen Sandhu et al. · New England Journal of Medicine · 2015 · 2.1K citations · Full text

Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial

David P. Dearnaley, Isabel Syndikus, Helen Mossop et al. · The Lancet Oncology · 2016 · 1.3K citations · Full text

Circulating Cell-Free DNA to Guide Prostate Cancer Treatment with PARP Inhibition

Jane Goodall, Joaquı́n Mateo, Wei Yuan et al. · Cancer Discovery · 2017 · 410 citations · Full text

Hypofractionated radiotherapy versus conventionally fractionated radiotherapy for patients with intermediate-risk localised prostate cancer: 2-year patient-reported outcomes of the randomised, non-inferiority, phase 3 CHHiP trial

Anna Wilkins, Helen Mossop, Isabel Syndikus et al. · The Lancet Oncology · 2015 · 149 citations · Full text

Clinical Outcome of Prostate Cancer Patients with Germline DNA Repair Mutations: Retrospective Analysis from an International Study

Joaquı́n Mateo, Heather H. Cheng, Himisha Beltran et al. · European Urology · 2018 · 119 citations · Full text